Hong Kong Stock IPO Weekly Report: Vaccine developer Lvzhu Biology submits form to Weitianyuntong and passes hearing
News from the Associated Press, February 19 (edited by Ma Yijie)The Financial Associated Press brings you Hong Kong stock IPO information this week.
As of press time, this week (February 13-February 19), a total of 2 companies submitted listing applications to the Hong Kong Stock Exchange, and 1 company passed the hearing.
Let’s look at the submission form first. This week, 2 companies submitted forms to the Hong Kong Stock Exchange:
1) On February 13, Beijing Green Bamboo Biotechnology Co, Ltd submitted a listing application to the main board of the Hong Kong Stock Exchange, and CICC was its sole sponsor.
The prospectus reveals that Green Bamboo Bio is committed to developing innovative human vaccines and therapeutic biological agents to prevent and control infectious diseases and treat cancer and autoimmune diseases. The company plans to build a new research and development and production facility in Beijing in the second quarter of 2023, with construction expected to be completed in the first quarter of 2024; the total production capacity of the new facility is expected to be 8 million doses. of recombinant varicella vaccine and 4 million doses of recombinant rabies vaccine per year. According to financial data, between 2021 and 2022, Green Bamboo Biotech has no temporary product sales revenue, and other revenue is 6.896 million yuan and 13.923 million yuan respectively; while research and development expenditure was 42.983 million yuan and 91.426 million yuan respectively in the same. period.
2) On February 17, Zhenhe Technology Group submitted a form to the main board of the Hong Kong Stock Exchange, and CICC and Merrill Lynch were its co-sponsors. The company had a delivery record on September 26, 2022.
According to the prospectus, Zhenhe Technology is an innovative molecular tumor diagnosis and detection company in China. The company currently has 20 commercial products and services, and 16 research products and services at various stages of development. Financial data shows that Zhenhe Technology’s income mainly comes from central laboratory business, hospital admission business and other services. In the three fiscal years between 2020 and 2022, the company’s operating income was 304 million yuan, 393 million yuan, and 435 million yuan; research and development expenditure was 137 million yuan, 176 million yuan, and 250 million yuan; the former tax; losses for the same period were 581 million yuan. , 407 million yuan and 429 million yuan.
Look at the hearing again This week, the company passed the Hong Kong Stock Exchange hearing.
1) On February 13, Hefei Weitian Yuntong Information Technology Co, Ltd passed the Hong Kong Stock Exchange listing hearing, with Haitong International as its sole sponsor.
According to the prospectus, Way-Tianyuntong is mainly involved in the road freight digital ecosystem business. According to China Insights Consulting, during the record period, the company operated one of the largest digital freight platforms in China regarding GTV online. Financial data shows that between 2019 and 2021 and the first nine months of 2022, the company’s revenue will be about 3.561 billion yuan, 4.665 billion yuan, 6.297 billion yuan and 4.711 billion yuan; gross profit will be about 212 million yuan, 301 million yuan; , 400 million yuan, respectively 100 million yuan and 259 million yuan.
